GlassScriptPhysician profile
Maurizio Cervone
NPI 1174653331
$7,433.51
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $28.13 · 2021: $66.21 · 2022: $7,190.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,165.00 | 2022 | |
| Amarin Pharma, INC. | $133.92 | 2019-2021 | |
| Genentech USA, INC. | $69.27 | 2019-2021 | |
| Pfizer INC. | $14.72 | 2019 | |
| Esperion Therapeutics, INC. | $14.27 | 2021 | |
| Althera Pharmaceuticals LLC | $13.06 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.12 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.15 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurizio Cervone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.